```
(FILE 'HOME' ENTERED AT 12:20:49 ON 20 FEB 2008)
           FILE 'MEDLINE, AGRICOLA, WPIX, BIOSIS, ESBIOBASE, CONFSCI, CAPLUS,
           DISSABS, EMBASE, SCISEARCH' ENTERED AT 12:21:05 ON 20 FEB 2008
                          894 S (FADS2 OR DELTA6-DESATURASE OR LINOLEOYL-COA DESATURASE)
L2
                              2 S L1 AND PRESENILIN
L3
                              1 DUP REM L2 (1 DUPLICATE REMOVED)
L4
                              2 S L1 AND NICASTRIN
L5
                              1 DUP REM L2 (1 DUPLICATE REMOVED)
L6
                              6 S L1 AND APP
T.7
                              4 DUP REM L6 (2 DUPLICATES REMOVED)
L8
                              0 S L1 AND NOTCH
L9
                              2 S L1 AND BACE
L10
                              2 DUP REM L9 (0 DUPLICATES REMOVED)
L11
                              6 S L1 AND ALZHEIMER
L12
                              5 DUP REM L11 (1 DUPLICATE REMOVED)
=> s 111 and (gamma-secretase)
                            2 L11 AND (GAMMA-SECRETASE)
=> dup rem 113
PROCESSING COMPLETED FOR L13
                               1 DUP REM L13 (1 DUPLICATE REMOVED)
=> d 114 ibib abs
L14 ANSWER 1 OF 1 WPIX COPYRIGHT 2008 THE THOMSON CORP on STN DUPLICATE
ACCESSION NUMBER:
                                             2005-223334 [23] WPIX
CROSS REFERENCE:
                                               2005-242127; 2005-591561; 2005-591643; 2005-597796;
                                                2005-684094; 2006-164656; 2006-164657; 2006-414402
DOC. NO. CPI:
                                                C2005-071587 [23]
TITLE:
                                             Use of a FADS2 interacting molecule for
                                             preparing a pharmaceutical composition for treating
                                                neurodegenerative diseases
DERWENT CLASS:
                                             B04; D16
INVENTOR:
                                             HOPF C; DREWES G; RUFFNER H
PATENT ASSIGNEE: (CELL-N) CELLZOME AG
COUNTRY COUNT: 107
PATENT INFO ABBR.:
             PATENT NO KIND DATE WEEK LA PG MAIN IPC
             WO 2005023833 A2 20050317 (200523)* EN 488[7]
            The property of the property o
              EP 1670903 B1 20070829 (200757) EN
              DE 602004008658 E 20071011 (200782) DE
APPLICATION DETAILS:
             PATENT NO KIND
                                                                                            APPLICATION DATE
```

WO 2005023833 A2 WO 2004-EP9771 20040902

```
EP 1670903 A2
                                    EP 2004-764730 20040902
EP 1670903 B1
                                    EP 2004-764730 20040902
EP 1670903 A2
                                    WO 2004-EP9771 20040902
US 20060216292 A1
                                    WO 2004-EP9771 20040902
EP 1670903 B1
                                    WO 2004-EP9771 20040902
US 20070161554 A1
                                    WO 2004-EP13457 20041126
                                    CN 2004-80042303 20041129
CN 1925869 A
IN 2006CN02799 P4
                                    WO 2004-EP13538 20041129
US 20060216292 A1
                                    US 2006-570909 20060329
                                    IN 2006-CN2799 20060728
IN 2006CN02799 P4
                                    US 2007-594213 20070119
US 20070161554 A1
DE 602004008658 E
                                    DE 2004-602004008658 20040902
DE 602004008658 E
                                    EP 2004-764730 20040902
DE 602004008658 E
                                    WO 2004-EP9771 20040902
```

PATENT NO

## FILING DETAILS:

PATENT NO KIND

EP	167090	3	A2	Based	on	WO	2005023833	3 A	
EP	167090	3	B1	Based	on	WO	2005023833	3 A	
DE	602004	008658	E	Based	on	EP	1670903	A	
DE	602004	008658	E	Based	on	WO	2005023833	3 A	
PRIORITY	APPLN.	INFO:	EP	2004-188	74	200	10809		
			EP	2003-1964	12	2003	30905		
			WO	2003-EP13	3980	2003	31210		
			EP	2004-1894	1	2004	10129		
			EP	2004-1895	5	200	10129		
			EP	2004-744	7	200	10326		
			WO	2004-EP48	391	200	10507		
			WO	2004-EP48	389	200	10507		
			DE	2004-1020	004007447	200	10326		
			US	2007-5942	213	200	70119		
AN 200	5-22333	4 [23]	Þ	WPIX					

CR 2005-242127; 2005-591561; 2005-591643; 2005-597796; 2005-684094;

2006-164656; 2006-164657; 2006-414402

AB WO 2005023833 A2 UPAB: 20060122

NOVELTY - A FADS2 interacting molecule useful for preparing a pharmaceutical composition for treating neurodegenerative diseases, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) identifying a gamma secretase and/or beta
- secretase inhibitor;
- (2) preparing a pharmaceutical composition for treating neurodegenerative diseases;
  - (3) a protein complex comprising FADS2 and one or more proteins of the Nicastrin, BACE1, PTK7 or Psen2 complex:
- (4) preparing and optionally analyzing the complex or its components;
- (5) a nucleic acid construct containing one or more nucleic acids encoding the proteins of the complex;
  - (6) a host cell containing the nucleic acid construct;
    - (6) a host cell containing the nucleic acid construct;
      (7) a kit comprising in one container the complex, optionally
- together with an antibody against the complex and/or further components such as reagents and working instructions;
- (8) an array in which at least the complex is attached to a solid carrier;
  - (9) a process for processing a substrate of the complex;
  - (10) a pharmaceutical composition comprising the protein complex;

- (11) screening for a molecule that binds to the complex; (12) screening for a molecule that modulates directly or indirectly
- the function, activity, composition or formation of the complex; (13) producing the pharmaceutical composition;
- (14) diagnosing or screening for the presence of a disorder or predisposition for developing a disorder characterized by aberrant amount, component disposition or intracellular localization of the complex; and
- (15) treating or preventing a disorder characterized by aberrant amount, component disposition or intracellular localization of the complex.

ACTIVITY - Neuroprotective. No biological data given.

MECHANISM OF ACTION - Gene therapy.

USE - The FADS2 interacting molecule is useful for modulating gamma secretase and/or beta secretase activity in vitro. The FADS2 interacting molecule is useful for modulating the amount, activity or protein components of the complex for preparing a pharmaceutical composition for diagnosing, treating or preventing neurodegenerative diseases, e.g., Alzheimer's disease. The complex is useful as a target for an active agent of a pharmaceutical composition for treating or preventing neurodegenerative diseases e.g., Alzheimer's disease. (All claimed.)

## => d his

## (FILE 'HOME' ENTERED AT 12:20:49 ON 20 FEB 2008)

FILE 'MEDLINE, AGRICOLA, WPIX, BIOSIS, ESBIOBASE, CONFSCI, CAPLUS, DISSABS, EMBASE, SCISEARCH' ENTERED AT 12:21:05 ON 20 FEB 2008

- L1 894 S (FADS2 OR DELTA6-DESATURASE OR LINOLEOYL-COA DESATURASE)
  - 2 S L1 AND PRESENILIN
- L3 1 DUP REM L2 (1 DUPLICATE REMOVED)
- L4 2 S L1 AND NICASTRIN L5 1 DUP REM L2 (1 DUPLICATE REMOVED)
- L6 6 S L1 AND APP
- 4 DUP REM L6 (2 DUPLICATES REMOVED) L7
- L8 0 S L1 AND NOTCH
- L9 2 S L1 AND BACE
  - 2 DUP REM L9 (0 DUPLICATES REMOVED)
- L10 6 S L1 AND ALZHEIMER L11
- 5 DUP REM L11 (1 DUPLICATE REMOVED) 2 S L11 AND (GAMMA-SECRETASE) L12
- L13
- L14 1 DUP REM L13 (1 DUPLICATE REMOVED)

L2